Sign In
Buy ARGX
$844.50
+13.71 (+1.65%)
At Close: Aug 04, 2026
argenx: Another Strong Quarter For Vyvgart
09:24am, Tuesday, 02'nd Aug 2022
argenx reported another strong quarter with $74.9 million in Vyvgart net sales. The company added 1,000 new patients in Q2, up from 400 in Q1.
Argenx's Vyvgart To 'Achieve Blockbuster Status,' This Analyst Says With 6% Price Target Hike
06:03pm, Friday, 29'th Jul 2022 Benzinga
HC Wainwright is bullish on Argenx SE's (NASDAQ: ARGX) Vyvgart (efgartigimod). "We think it's becoming obvious that Vyvgart is going to be a blockbuster sooner rather than later, as it establishes
Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022
02:31pm, Friday, 29'th Jul 2022 Benzinga
Upgrades
For The Carlyle Group Inc (NASDAQ:CG), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. Carlyle Group earned $1.17 in the second quarter, compared to $0.88 in the ye
argenx SE (ARGX) Q2 2022 Earnings Call Transcript
12:00am, Friday, 29'th Jul 2022 The Motley Fool
ARGX earnings call for the period ending June 30, 2022.
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2022 Results - Earnings Call Transcript
01:00pm, Thursday, 28'th Jul 2022
argenx SE (NASDAQ:ARGX ) Q2 2022 Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Beth DelGiacco - VP Corporate Communications and IR Tim Van Hauwermeiren - CEO Karl Gubitz - CFO
argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022
06:30am, Thursday, 28'th Jul 2022 GlobeNewswire Inc.
July 28, 2022
argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update
05:00am, Thursday, 28'th Jul 2022 GlobeNewswire Inc.
July 28, 2022
Piper Sandler Maintains Overweight Rating for argenx: Here's What You Need To Know
04:17pm, Monday, 25'th Jul 2022 Benzinga
Piper Sandler has decided to maintain its Overweight rating of argenx (NASDAQ:ARGX) and raise its price target from $415.00 to $425.00.
Shares of argenx are trading up 1.84% over the last 24 hours, at
argenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022
01:00am, Thursday, 21'st Jul 2022
July 21, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today annou
argenx: Biopharma Star
03:32pm, Wednesday, 06'th Jul 2022
100% technical buy signals. 11 new highs and up 15.30% in the last month.
argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe
05:00am, Friday, 24'th Jun 2022 GlobeNewswire Inc.
Breda, the Netherlands—June 24, 2022—argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today annou
Halozyme's (HALO) ENHANZE Drives Stock: Rally to Continue?
01:13pm, Tuesday, 21'st Jun 2022 Zacks Investment Research
Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs developed using ENHANZE. Robust revenue growth is expected to continue in 2022.
argenx to Present at Upcoming Investor Conferences
05:00am, Wednesday, 01'st Jun 2022 GlobeNewswire Inc.
June 1, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announc
argenx to Present at Upcoming Investor Conferences
01:00am, Wednesday, 01'st Jun 2022
June 1 , 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today annou
argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis
05:00am, Tuesday, 31'st May 2022 GlobeNewswire Inc.
Positive scientific opinion under Early Access to Medicines Scheme (EAMS) will make efgartigimod available to eligible generalized myasthenia gravis (gMG) patients in the UK prior to marketing authori
